Association of GLP ‐1 Receptor Agonist Use With Cardiovascular Outcomes and Mortality in Japanese Patients With Type 2 Diabetes: A Real‐World Claims Database Study
Main finding · 3-point MACEResult — go to the resultHazard ratio 0.920 95% CI 0.740–1.143Authors' conclusion
GLP-1RA showed no association with 3-point MACE difference but showed lower all-cause mortality. These findings possibly reflect residual confounding.
Study context
- Population
- Japanese patients with T2D from a claims database of ≈1.9 million individuals2,147 per group after matching
- Participants
- 469,461 patients
- Exposure
- GLP-1 RA vs other glucose-lowering agents
- GLP-1RAn = 2,147
- Controln = 2,147reference
- Outcome
- Cardiovascular or cerebrovascular events or all-cause mortality
- Follow-up
- Maximum 38 months
Methodological detailsclaims database, propensity-score matched
- Claims database
- Propensity-score matched
Main finding
3-point MACE · median follow-up 12 months
Hazard ratio
0.920
95% CI 0.740–1.143
P = 0.450
Events by group
GLP-1RAvs Control
HR 0.920 (95% CI 0.740–1.143); P = 0.450
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | GLP-1RA | Control | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| All-cause mortality | 5.36% | 7.36% | 0.776 (0.610–0.987) | P = 0.039 | |
| 0.512Hazard ratio (log scale) |
Original publication
Association of GLP ‐1 Receptor Agonist Use With Cardiovascular Outcomes and Mortality in Japanese Patients With Type 2 Diabetes: A Real‐World Claims Database Study. Diabetes Obes Metab. Published 11 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →